Physician profile
John Riser
NPI 1134216088
$44,050.23
in general payments reported to CMS, 2019-2025
61 companies · $6,952 in 2025
The $6,952 reported for 2025 was more than what 98% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $18K · 2020: $2,363 · 2021: $1,004 · 2022: $1,340 · 2023: $10K · 2024: $4,017 · 2025: $6,952.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $11K · Consulting Fee: $9,183 · Travel and Lodging: $719 · Education: $118.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $11,393.59 |
| Consulting Fee | $9,182.50 |
| Travel and Lodging | $719.29 |
| Education | $117.56 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alexion Pharmaceuticals, INC. | $13,195.97 | 2019-2025 | Ultomiris, Soliris |
| Genzyme Corporation | $10,344.34 | 2019-2025 | |
| Tanabe Pharma America, INC. | $5,124.36 | 2019-2025 | Radicava |
| Biogen, INC. | $1,300.28 | 2019-2025 | Vumerity, Tysabri, Leqembi |
| Emd Serono, INC. | $1,218.62 | 2019-2025 | Mavenclad |
| Neurocrine Biosciences, INC. | $998.10 | 2024-2025 | Ingrezza |
| Amgen INC. | $993.40 | 2019-2025 | Uplizna, Aimovig |
| Tg Therapeutics, INC. | $897.38 | 2023-2025 | |
| Celgene Corporation | $817.08 | 2019-2025 | Zeposia |
| Ucb, INC. | $800.66 | 2019-2025 | Rystiggo, Briviact, Zilbrysq |
| Mallinckrodt Hospital Products INC. | $712.59 | 2020-2025 | Acthar |
| Abbvie INC. | $706.21 | 2019-2025 | Ubrelvy, Qulipta, Botox |
| Pfizer INC. | $684.05 | 2019-2025 | |
| Genentech USA, INC. | $653.86 | 2022-2025 | Ocrevus, Ocrevus Zunovo, Enspryng |
| Argenx US, INC. | $560.89 | 2022-2025 | Vyvgart Hytrulo, Vyvgart |
Show all 59 companies
2 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Riser listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.